aripiprazole) Supplemental New Drug Application Receives Priority Review By U.S. Food And Drug Administration ...

Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted a Priority Review for the supplemental New Drug Application (sNDA) of ABILIFY® (aripiprazole) for the treatment of adults with major depressive disorder as adjunctive to antidepressant therapy (ADT). [click link for full ...
From: www.medicalnewstoday.com